Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622184 | 0.78 | LCK (0.43) | PARP1CES1AHRRETGRK5 | |
| SCHEMBL3046612 | 0.76 | AURKA (0.57) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL1585047 | 0.76 | AURKA (0.59) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL15648949 | 0.76 | AURKA (0.54) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL12654234 | 0.76 | AURKA (0.59) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL3484978 | 0.76 | AURKA (0.59) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL2027473 | 0.76 | TDP2 (0.58) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL12478097 | 0.76 | AURKA (0.50) | AURKAKDRCA12CA9PARP1 | |
| SCHEMBL798110 | 0.74 | PNMT (0.42) | CES1AHRRETGRK5TYRO3 | |
| SCHEMBL30626061 | 0.74 | AURKA (0.49) | AURKAKDRCA12CA9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088905-A | Asymmetric boron-fluorine pyrrole fluorescent dye, preparation method thereof and method for preparing fluorescent microspheres | 南京珀立科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| WO-2025089147-A1 | HERBICIDAL COMPOSITION | 株式会社エス・ディー・エス バイオテック | 2025-05-01 | — | — | WO | disclosed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| CN-118580225-A | PRMT5-MTA synergistic inhibitor and application thereof | 甘李药业股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | AURKA 79/4885KDR 1466/4885CA12 3443/4885 |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | AURKA 4077/4885KDR 1838/4885CA12 3672/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | AURKA 4077/4885KDR 1838/4885CA12 3672/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | AURKA 1550/4885KDR 521/4885CA12 3336/4885 |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | AURKA 2320/4885KDR 3706/4885CA12 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.